|Bid||85.00 x 0|
|Ask||88.00 x 0|
|Day's Range||85.03 - 87.40|
|52 Week Range||0.86 - 110.00|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.01 (1.49%)|
|Ex-Dividend Date||Nov 23, 2020|
|1y Target Est||84.00|
Beximco is Bangladesh's exclusive distributor of the Oxford University-AstraZeneca shot that SII, the world's biggest vaccine manufacturer, is producing in bulk for low- and medium-income countries. The Bangladeshi company last week received 5 million of the 30 million doses it had ordered from SII for Bangladesh's immunisation programme that begins next week. Beximco had separately ordered 1 million doses for sale on the private market, with the hope to start marketing it this month.
Bangladesh's Beximco Pharmaceuticals <BXPH.DH> is investing in the Serum Institute of India (SII) to ensure Dhaka gets priority access to COVID-19 vaccines being developed by the Indian drug manufacturer, the company said on Friday. The deal announced by the Bangladeshi generic drugmaker comes after Dhaka said this month it was ready to hold trials of candidate vaccines being developed by India as both countries seek to curb the spread of the virus. SII has partnered with AstraZeneca <AZN.L>, the Gates Foundation and the Gavi vaccine alliance to produce more than a billion doses of a COVID-19 vaccine for global supply.